Cyclic amine BACE-1 inhibitors having a benzamide substituent
View Patent ↗Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is R is —C(O)—N(R 27 )(R 28 ) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
1. A compound having the structural formula
or a pharmaceutically acceptable salt thereof, wherein
R 1 is
R is —C(O)—N(R 27 )(R 28 );
R 2 is difluorobenzyl;
R 3 is H or alkyl;
R 4 is H or alkyl;
R 8 is selected from the group consisting of H, OH, alkoxy, phenoxy or benzyloxy, wherein said alkoxy, said phenoxy, and said benzyloxy are unsubstituted or substituted by 1 to 5 independently selected R 32 groups;
R 14 is 1 to 4 substituents independently selected from the group consisting of H, alkyl, halo, —CN, haloalkyl,
R 27 and R 28 are independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, hydroxyalkyl, and alkoxyalkyl;
or R 27 and R 28 together with the nitrogen to which they are attached, form an unsubstituted 3-7 membered heterocycloalkyl ring, or a 3-7 membered heterocycloalkyl ring substituted by 1-3 substituents independently selected from the group consisting of alkyl, and alkoxyalkyl;
wherein each R 32 group is independently selected from the group consisting of halo, alkyl, cycloalkyl, cycloalkylalkyl, and —OR 35 ;
each R 35 is independently selected from the group consisting of H and alkyl.
2. A compound of claim 1 wherein R 3 and R 4 are hydrogen.
3. A compound of claim 1 wherein R 1 is
4. A compound of claim 1 having the stereochemical structure:
5. A compound of claim 1 selected from the group consisting of
6. The compound of claim 1 which is
7. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically effective carrier.
8. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , and an effective amount of a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody in a pharmaceutically effective carrier.
9. A composition of claim 8 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin, lovastatin, simvistatin, pravastatin, fluvastatin and rosuvastatin; the cholinesterase inhibitor is selected from the group consisting of atorvastatin, lovastatin, simvistatin, pravastatin, fluvastatin and rosuvastatin; the non-steroidal anti-inflammatory agent is selected from the group consisting of ibuprofen, naproxen, diclofenac, diflunisal, etodolac, flurbiprofen, indomethacin, ketoprofen, ketorolac, nabumetone, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib and rofecoxib; and the N-methyl-D-aspartate receptor antagonist is memantine.
10. A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination, in which one container comprises a compound of formula I in a pharmaceutically acceptable carrier and a second container comprises a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody in a pharmaceutically acceptable carrier.